SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'ev2ebitda' CureVac NV (WBO:CVAC) EV-to-EBITDA
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » EV-to-EBITDA

CureVac NV (WBO:CVAC) EV-to-EBITDA

: -0.32 (As of Today)
View and export this data going back to 2020. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CureVac NV's enterprise value is €88.91 Mil. CureVac NV's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was €-275.17 Mil. Therefore, CureVac NV's EV-to-EBITDA for today is -0.32.

The historical rank and industry rank for CureVac NV's EV-to-EBITDA or its related term are showing as below:

WBO:CVAC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -191.1   Med: -8.01   Max: -0.32
Current: -0.32

During the past 5 years, the highest EV-to-EBITDA of CureVac NV was -0.32. The lowest was -191.10. And the median was -8.01.

WBO:CVAC's EV-to-EBITDA is ranked worse than
100% of 471 companies
in the Biotechnology industry
Industry Median: 9.01 vs WBO:CVAC: -0.32

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-20), CureVac NV's stock price is €2.362. CureVac NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €-1.470. Therefore, CureVac NV's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


CureVac NV EV-to-EBITDA Historical Data

The historical data trend for CureVac NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
- - -110.54 -12.66 -2.94

CureVac NV Quarterly Data
Dec18 Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.36 -2.94 -3.36 -6.11 -3.66

Competitive Comparison

For the Biotechnology subindustry, CureVac NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, CureVac NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CureVac NV's EV-to-EBITDA falls into.



CureVac NV EV-to-EBITDA Calculation

CureVac NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=88.907/-275.168
=-0.32

CureVac NV's current Enterprise Value is €88.91 Mil.
CureVac NV's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-275.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV  (WBO:CVAC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CureVac NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.362/-1.470
=At Loss

CureVac NV's share price for today is €2.362.
CureVac NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.470.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


CureVac NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CureVac NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (WBO:CVAC) Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.